PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of pembrolizumab for locally advanced uterine cervical cancer, and durvalumab and olaparib for advanced or recurrent endometrial cancer in Japan

Int J Clin Oncol. 2024 Dec 28. doi: 10.1007/s10147-024-02679-w. Online ahead of print.

Noriomi Matsumura^{1

2}, Masaki Mandai^{3

4}

¹ Faculty of Medicine, Kindai University, Osaka, Japan. [email protected].
² Japan Society of Clinical Oncology, Editorial Committee, Tokyo, Japan. [email protected].
³ Japan Society of Clinical Oncology, Editorial Committee, Tokyo, Japan.
⁴ Kyoto University Graduate School of Medicine, Kyoto, Japan.

No abstract available

Publication types